Focal One: The Machine That Destroys Cancer Without an Incision

In a treatment room in Lyon, France, a patient lies still on a padded table. There is no scalpel in sight. No incision will be made. No blade will enter the body. Yet over the next hour, a machine the size of a small car will destroy a tumour inside him, deeper than any surgeon's hand could reach, using nothing but sound.

The machine is called Focal One. The technology it uses is called High Intensity Focused Ultrasound, or HIFU. And it is quietly reshaping the way the world treats cancer.

The Magnifying Glass Principle

Every child who has burned a leaf with a magnifying glass under the summer sun already understands how HIFU works. Sunlight passes harmlessly through the glass. But at the exact focal point where the rays converge, the concentrated energy becomes hot enough to ignite paper.

Focal One does the same thing with ultrasound waves instead of light.

Sound waves at a frequency far above human hearing, around 3 MHz, are aimed through the skin from a curved transducer. Along the path, the waves are harmless. They pass through healthy tissue without damaging it. But at the geometric focal point, sometimes no larger than a grain of rice, the waves converge and the temperature rockets to between 60 and 90 degrees Celsius in a single second. The cancer cells at that exact spot die instantly through a process called coagulation necrosis. Everything around them, even tissue a few millimetres away, remains untouched.

It is cancer treatment without surgery. Ablation without incision. No blood loss. No general trauma. A patient often walks out the same day.

Why Cancer Doctors Are Paying Attention

For decades, the standard options for solid tumours were brutal: surgery, radiation, or chemotherapy. Each carried serious side effects. Surgery meant scars and long recoveries. Radiation damaged healthy tissue. Chemotherapy attacked the entire body to kill cells in one location.

HIFU offered a fourth option. Precise. Non-invasive. Repeatable. If a tumour returned, the treatment could simply be performed again.

Focal One is built by a French company called EDAP TMS, founded in Lyon in 1979. EDAP spent nearly four decades perfecting therapeutic ultrasound before launching Focal One in Europe in 2013. In June 2018, the device received FDA 510(k) clearance in the United States for tumour ablation. In September 2025, the French Ministry of Health approved national reimbursement for HIFU cancer procedures on Focal One, placing it on equal financial footing with traditional surgery.

The engineering is remarkable. Focal One's transducer contains 16 isocentric rings, each with an independent power supply, allowing the focal point to be steered electronically with submillimetric accuracy. The surgeon loads MRI scans and 3D biopsy data into proprietary software called HIFUsion, which fuses them with live ultrasound. A three-dimensional map of the tumour appears on a monitor. The surgeon draws the contour. The robot executes the plan in 5 mm increments, up to 40 mm in length.

Cancer by Cancer, the Map Is Expanding

Focal One began with a single type of cancer, but the underlying HIFU science is being studied across the oncology spectrum.

Clinical trials and approved uses now cover cancers of the breast, liver, pancreas, kidney, bone, and thyroid. An international review led by Dr. Alessandro Napoli at Sapienza University of Rome documented HIFU being used to destroy early-stage tumours, shrink inoperable late-stage ones, and palliate the pain of cancers that had spread to bone. For women with uterine fibroids, studies show HIFU produces symptom reduction comparable to surgery at twelve months, without a single cut.

In March 2024, the FDA granted Focal One a Breakthrough Device Designation for deep infiltrating endometriosis. In 2006, researchers even showed HIFU could ablate brain tumours through the intact skull. Today, the same acoustic principle is used to treat Parkinson's tremors by targeting a tiny region deep inside the brain, without drilling a single hole.

Why This Matters for Tomorrow's Careers

The story of Focal One is not just a medical story. It is a story about the future of work.

HIFU sits at the intersection of five disciplines: acoustic physics, robotics, medical imaging, artificial intelligence, and clinical oncology. The engineers who design the phased-array transducers need advanced signal processing. The software teams building HIFUsion need to master elastic image fusion, an AI-driven technique where MRI and ultrasound images, captured at different times under different conditions, are mathematically aligned to subpixel accuracy.

The next breakthrough in cancer treatment will not come from a single brilliant surgeon. It will come from a team where a radiologist, a machine learning engineer, a biomedical physicist, and a clinical researcher all speak each other's language. Students growing up today will not just use these machines. They will build them, train them, and invent the next generation.

How Futurowise Can Help

At Futurowise, our Data Science programme equips students to think in systems, understand complex data, and engage with the interdisciplinary challenges that define careers in medical technology and AI-driven cancer care. Our Public Speaking programme ensures they can articulate ideas, lead conversations, and communicate with confidence in a world that rewards clarity. The students who understand how Focal One and HIFU work today will be the ones shaping the next wave of non-invasive cancer treatment tomorrow.

Explore our programmes: www.futurowise.com/courses